RLAY News and Press, Relay Therapeutics Inc. From 03/24/23

2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group –  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that initial clinical data f...

Relay Therapeutics press release ( NASDAQ: RLAY ): Q4 GAAP EPS of -$0.56 beats by $0.14 . Revenue of $0.25M (-56.1% Y/Y) beats by $0.08M . Approximately $1 billion in cash, cash equivalents and investments at end of 2022, expected to fund operations into 2025 For...

Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced anticipated registrational path Progressed & expanded breast cancer portfolio: ...

Summary Relay's share price was hammered throughout 2022, losing >70% of its value. That may have been down to short-termism since Relay has built a credible pipeline in a short space of time. The company uses a cutting-edge AI-driven drug discovery engine to model disease-causin...

CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year ...

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 9, 2023 at 10:10 a.m. ET. The fireside chat will be webcast live and may be access...

Summary Relay Therapeutics, Inc. discovers drugs using a novel computational approach. There is some proof of concept data. However, Relay Therapeutics, Inc.'s safety profile and high valuation are deterrents. For further details see: Relay Therapeutics: Ta...

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to present at the 41 st Annu...

Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society for Medical Oncology (ESMO) Congress $1.1 billion in cash, cash eq...